Navigation Links
Gen-Probe Begins U.S. Clinical Study of Molecular Test for Human Papillomavirus, Which Causes Cervical Cancer
Date:3/31/2008

SAN DIEGO, March 31 /PRNewswire-FirstCall/ -- Gen-Probe Incorporated (Nasdaq: GPRO) announced today that the Company has begun a pivotal U.S. clinical trial of its investigational APTIMA(R) assay to detect human papillomavirus (HPV), which causes cervical cancer.

"Starting this highly complex, multi-center study was an important goal for Gen-Probe in early 2008," said Carl Hull, the Company's president and chief operating officer. "Enrolling our first patient last week is a testament to the hard work of our integrated product development team. We expect that their extensive efforts to date will ultimately result in the introduction of a highly accurate APTIMA HPV assay that improves the detection and treatment of cervical cancer."

The investigational APTIMA HPV assay is an amplified nucleic acid test that detects 14 high-risk HPV types that are associated with cervical cancer. More specifically, the assay detects two messenger RNAs (mRNAs), E6 and E7, that are made in higher amounts when HPV infections progress toward cervical cancer. Gen-Probe believes that targeting these mRNAs may more accurately identify women at higher risk of having, or developing, cervical cancer than competing assays that target HPV DNA. Detecting HPV DNA identifies women who are infected, but HPV infections are common and many resolve without causing cervical cancer.

Women undergoing routine Pap testing at participating U.S. clinics are eligible to participate in the clinical study, which includes two arms. One arm enrolls women whose Pap results are classified as ASC-US (atypical squamous cells of undetermined significance), meaning they are neither normal nor clearly indicative of changes associated with progression to cervical cancer. In t
'/>"/>

SOURCE Gen-Probe Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Gen-Probe Submits U.S. Regulatory Application for Additional Approval of PROCLEIX(R) ULTRIO(R) Blood Screening Assay
2. Gen-Probe Announces Webcast of Third Quarter 2007 Earnings Conference Call
3. Catalyst Pharmaceutical Partners Begins Enrollment for Its U.S. Phase II Clinical Trial of CPP-109 in Patients with Cocaine Addiction
4. Genaera Begins Dosing Second Phase 1 Trial of Type 2 Diabetes and Obesity Compound Trodusquemine (MSI-1436)
5. Cogentus Pharmaceuticals Begins Clinical Study to Confirm the Full Antiplatelet Benefit of New Combination Medicine CGT-2168
6. Nuvelo Begins Phase 2 Trial and Receives Fast Track Status for Alfimeprase in Patients With Acute Ischemic Stroke
7. BiPar Begins Phase 2 Study of Lead PARP Inhibitor in Triple-Negative Breast Cancer Based on Overexpression Biomarker Data
8. Dynavax Begins TOLAMBA(TM) Environmental Exposure Chamber Study
9. Rockwell Medical Technologies, Inc. Begins Dosing Patients for SFP Phase IIb Clinical Study
10. DiObex Begins Dosing Patients in Phase 2b Trial of Type 2 Diabetes Drug
11. Metabolex Begins Phase 2 Trial of MBX-8025 for Treatment of Dyslipidemia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... , Sept. 2, 2015 Research and ... of Jain PharmaBiotech,s new report "Drug Delivery ... and Companies" to their offering. ... of the BBB have opened new avenues and ... Several carrier or transport systems, enzymes, and receptors ...
(Date:9/2/2015)... Sept. 2, 2015  Boca Raton Regional Hospital,s ... begun performing ultra-minimally invasive left atrial appendage ligation ... such as Coumadin, Xarelto or Effient. Dr. Cartledge, ... Hospital, is one of a select group of ... two microscopic incisions in order to seal off ...
(Date:9/2/2015)... , Sept. 2, 2015 Simplified Genetics ... for improved fitness, health and safety in the U.S., announced ... the personal roadmap to improved overall health found within specific ... of your cheek. The tests include ... is a full sequence genetic analysis that maps four key ...
Breaking Medicine Technology:Drug Delivery in Central Nervous System Diseases - Technologies, Markets and Companies Report 2015-2024 2Drug Delivery in Central Nervous System Diseases - Technologies, Markets and Companies Report 2015-2024 3Boca Regional Introduces Ultra-Minimally Invasive Surgical Procedure for Atrial Fibrillation Patients 2Boca Regional Introduces Ultra-Minimally Invasive Surgical Procedure for Atrial Fibrillation Patients 3Simplified Genetics Decodes DNA's Blueprint for Individual Health and Safety 2Simplified Genetics Decodes DNA's Blueprint for Individual Health and Safety 3
... Medical Hematology and Oncology CHU Lapeyronie, Montpellier ... that has long been recognized as a marker ... range of diagnostic markers to monitor infection and ... a necessity throughout the health care sector, it ...
... ,Since the first system was invented in 1957, ... patient care. During the 1960s, blood gas analysis ... considered "the most important laboratory test for critically ... Dr. John Severinghaus, inventor of the blood gas ...
Cached Medicine Technology:Near-Patient Testing: The Advantages of C-Reactive Protein in Hematological Testing 2Near-Patient Testing: The Advantages of C-Reactive Protein in Hematological Testing 3Near-Patient Testing: The Advantages of C-Reactive Protein in Hematological Testing 4Blood Gas Analysis: The Pros and Cons of Point-Of-Care Testing 2Blood Gas Analysis: The Pros and Cons of Point-Of-Care Testing 3Blood Gas Analysis: The Pros and Cons of Point-Of-Care Testing 4
(Date:9/2/2015)... ... September 02, 2015 , ... According to an article published August 12 by International ... aims to do away with grand juries in cases meant to decide if a police ... response to grand jury decisions in Ferguson and New York City that absolved police officers ...
(Date:9/2/2015)... ... September 02, 2015 , ... ... – in the news recently following a decision by the Centers for Medicare ... is likely to average approximately $71,000 or roughly 40% of its headline-grabbing $178,000 ...
(Date:9/2/2015)... ... September 02, 2015 , ... ... announced today the launch of its enhanced, cloud-based mobile ePrescribing application. The release ... focus on improving prescriber usability. A leader in health technology, RxNT was one ...
(Date:9/2/2015)... , ... September 02, 2015 , ... ... incoming goods, intermediate or final products. Automating sample handling makes density measurements more ... handling, showing each step of the automated workflow and the advantages compared to ...
(Date:9/2/2015)... ... September 02, 2015 , ... A UPMC and ... earned international recognition as a premier center for treatment of and research into ... internal bleeding and stroke. , Cure HHT, previously known as The HHT ...
Breaking Medicine News(10 mins):Health News:Article on Recent Grand Jury Law Brings Increased Accountability to Wrongful Death Cases, says the Law Offices of Burg & Brock 2Health News:Article on Recent Grand Jury Law Brings Increased Accountability to Wrongful Death Cases, says the Law Offices of Burg & Brock 3Health News:Analysis Shows Amgen’s Leukemia Drug, Blincyto, Will Cost 60% Less than Highly Publicized $178,000 Price Tag 2Health News:Analysis Shows Amgen’s Leukemia Drug, Blincyto, Will Cost 60% Less than Highly Publicized $178,000 Price Tag 3Health News:Analysis Shows Amgen’s Leukemia Drug, Blincyto, Will Cost 60% Less than Highly Publicized $178,000 Price Tag 4Health News:RxNT Releases Enhanced ePrescribing iPhone App to Improve Prescriber Usability 2Health News:New Video from METTLER TOLEDO Shows the Advantages of Sample Handling Automation in Density Determination 2Health News:New Video from METTLER TOLEDO Shows the Advantages of Sample Handling Automation in Density Determination 3Health News:UPMC-University of Pittsburgh Named Center of Excellence for Rare Disorder 2Health News:UPMC-University of Pittsburgh Named Center of Excellence for Rare Disorder 3Health News:UPMC-University of Pittsburgh Named Center of Excellence for Rare Disorder 4
... on the development and commercialization of proprietary pharmaceuticals ... partners , today announced that under the Special ... with the United States Food and Drug Administration ... protocol for crofelemer for the treatment of chronic ...
... Functional foods could be the rage today in advanced ... better ask some tough questions before they decide ... ,Currently the international functional foods market is a ... ,* Margarines that lower bad cholesterol (LDL). ...
... at the University of Southern California have applied a ... clear up an old puzzle of the global carbon ... an advanced online publication of The ISME Journal. ... for nanometer-scale, secondary ion mass spectrometry) located at Lawrence ...
... to get hookah smoking exempted from Englands smoking ban ... the health effects , doctors writing in this weeks ... ,A hookah is a glass based waterpipe used ... for smoking herbal fruits after meals, but it is ...
... disease gives a more accurate measure of how many UK ... adults are most likely to benefit from treatment . ... the general population without pre-existing cardiovascular disease or diabetes, there ... Britain at high risk of developing heart disease. This is ...
... and Children's Hospital, Adelaide in Australia has raised serious questions ... are exposed to every day. ,Titled The ... ageing facilities in two of the hospital's oldest buildings and ... ,It states: "WCH is experiencing immediate facilities, infrastructure and related ...
Cached Medicine News:Health News:Napo Obtains Special Protocol Assessment Agreement From FDA for Crofelemer 2Health News:Functional Food What is That, Ask First 2Health News:Functional Food What is That, Ask First 3Health News:Nanospectrometer Aids in Identifying Nutrient Cycle 2Health News:Ban on Hookah Smoking Should Stay, Argue Doctors 2Health News:New Heart Disease Risk Score Will Help Minimise Health Inequalities 2Health News:New Heart Disease Risk Score Will Help Minimise Health Inequalities 3Health News:Concerns Raised Over Risks for Patients and Staff in Australian Hospital 2
New system has all of the features of the EPT-1000TC. Now with 100 watts RF power using the Blazer II XP catheter....
6.5mm diameter handpiece; 75mm handle with grooves for grip; Standard male luer taper fits most cannula hub and female luer taper....
45 degree angled; 5mm from bend to tip; overall length excluding hub 16mm; In Stainless Steel...
3 Piece with .35mm Angled Point, Curved to Left, #8, Side Opening Irrigation, 40mm overall length; in stainless steel; 30cm Long Silicone Tubing with Connector....
Medicine Products: